Comparison of Beinaglutide Versus Metformin for Weight Loss in Overweight and Obese Non-diabetic Patients
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Purpose We compared the efficacy and safety of beinaglutide, a glucagon-like peptide-1 (GLP-1) analogue with metformin in lowering the bodyweight of patients who were overweight/obese and non-diabetic. Patients and Methods Seventy-eight non-diabetic patients were randomly selected and beinaglutide or metformin was administered for 12 weeks. The primary endpoints were changes in body weight and the proportions of patients who lost≥5 and≥10% of their baseline body weights. Results A total of 64 patients completed the study; patients in the beinaglutide group exhibited more bodyweight loss than those in the metformin group [(9.5±0.8%; 9.1±0.9 kg) and (5.1±0.9%; 4.5±0.8 kg), respectively, corresponding to a difference of approximately 4.5 kg (95% confidence interval, 2.2–6.9 kg; P<0.01)]. In the beinaglutide group, 90.6 and 40.6% of the patients lost≥5 and≥10% of their body weight, respectively, whereas, in the metformin group, these rates were 46.9 and 12.5%, respectively (P<0.01 and P<0.05). Weight loss following beinaglutide treatment mainly resulted from the loss of fat mass. Compared to metformin, beinaglutide induced a greater decrease in the body mass index, weight circumference, percent body fat, and body fat mass (total, trunk, limb, android, and gynoid). Additionally, beinaglutide decreased serum insulin levels and ameliorated insulin resistance. Conclusions Beinaglutide is more efficient than metformin at reducing weight and fat mass in patients who are overweight/obese and non-diabetic. Beinaglutide may be a useful therapeutic option for overweight/obesity control in the Chinese population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Beinaglutide was the first original drug approved for the treatment of obesity in China and the third GLP-1 class reduction drug approved worldwide, and it represents a new treatment option for overweight and obese patients.67,118,119”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [118]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“A clinical study involving 78 non-diabetic overweight/obese patients found that BN may be a more effective treatment option for overweight/obese Chinese than metformin (43).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [43]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724 · cited 13×
“GLP-1RAs have been shown to reduce body weight in patients with T2DM and/or obese/overweight patients by suppress - ing appetite and delaying gastric emptying.”
InfluentialArmstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · cited 1×
“Additionally, one year of treatment with liraglutide improved pathological changes in patients with non-alcoholic steatohepatitis [32].”
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 2×
“GLP-1RAs have been shown to regulate postprandial glucagon release and insulin secretion in a glucose-dependent manner [30, 33].”
Blundell, J. E., Baker, J. L., Boyland, E., Blaak, E., Charzewska, J., de Henauw, S., Frühbeck, G., Gonzalez-Gross, M., Hebebrand, J., Holm, L., et al. (2017) · Obesity Facts · doi:10.1159/000455952 · Cited by 1,945
Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
Apovian, C. M., Aronne, L. J., Bessesen, D. H., McDonnell, M. E., Murad, M. H., Pagotto, U., Ryan, D. H., & Still, C. D. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3415 · Cited by 1,347 · cited 1×
“0 mg/d) is approved for weight loss treatment in patients with obesity among all hypoglycaemic drugs [26].”
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311 · cited 1×
“Different from other GLP-1RAs, beinaglutide is a recombinant GLP-1 that has 100 % homology to human GLP-1, and so can simulate the physiological mode of action of GLP-1, reduce food intake by suppressing appetite and delaying gastric emptying when injected before each meal [13].”
Bray, G. A., Frühbeck, G., Ryan, D. H., & Wilding, J. P. H. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00271-3 · Cited by 1,036 · cited 2×
“In West - ern countries, liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), is used for weight loss in non-diabetic obese pa - tients [5, 7].”
Vilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Based on previous studies [10, 22], GLP1RAs and metformin decreased body weight by around 3.”
Dombrowski, S. U., Knittle, K., Avenell, A., Araujo-Soares, V., & Sniehotta, F. F. (2014) · BMJ · doi:10.1136/bmj.g2646 · Cited by 816 · cited 1×
“Although lifestyle intervention is considered the cornerstone for the treatment of overweight and obese individuals, it is difficult to maintain weight loss using this approach alone [6].”
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814
Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion · doi:10.1185/030079908x253870 · Cited by 699 · cited 4×
“Beinaglutide and metformin treatments caused significant ( P < 0.05) and similar reductions in serum ALT and AST levels (▶ table 1 ).”
Influential8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2018
American Diabetes Association (2018) · Diabetes Care · doi:10.2337/dc18-s008 · Cited by 699
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680 · cited 1×
“GLP-1RAs have been shown to regulate postprandial glucagon release and insulin secretion in a glucose-dependent manner [30, 33].”
Ma, C., Avenell, A., Bolland, M., Hudson, J., Stewart, F., Robertson, C., Sharma, P., Fraser, C., & MacLennan, G. (2017) · BMJ · doi:10.1136/bmj.j4849 · Cited by 464
Uric Acid Secretion from Adipose Tissue and Its Increase in Obesity
Tsushima, Y., Nishizawa, H., Tochino, Y., Nakatsuji, H., Sekimoto, R., Nagao, H., Shirakura, T., Kato, K., Imaizumi, K., Takahashi, H., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.485094 · Cited by 393 · cited 1×
“The amount of adipose tissue is closely related to uric acid se - cretion, and that patients who are overweight/obese often exhib - it hyperuricaemia, whereas fat loss, particularly visceral fat loss, significantly reduces uric acid secretion [34].”
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384
Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis
Domecq, J. P., Prutsky, G., Leppin, A., Sonbol, M. B., Altayar, O., Undavalli, C., Wang, Z., Elraiyah, T., Brito, J. P., Mauck, K. F., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3421 · Cited by 334 · cited 1×
“Based on previous studies [10, 22], GLP1RAs and metformin decreased body weight by around 3.”
Overweight, Obesity, and Blood Pressure: The Effects of Modest Weight Reduction
Mertens, I. L., & van Gaal, L. F. (2000) · Obesity Research · doi:10.1038/oby.2000.32 · Cited by 330
Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
Jendle, J., Nauck, M. A., Matthews, D. R., Frid, A., Hermansen, K., Düring, M., Zdravkovic, M., Strauss, B. J., Garber, A. J., & Groups, O. B. O. T. L. A. L. S. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01158.x · Cited by 312
Effectiveness of Metformin on Weight Loss in Non-Diabetic Individuals with Obesity
Seifarth, C., Schehler, B., & Schneider, H. (2012) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0032-1327734 · Cited by 258 · cited 11×
“Similar to a previous study examining weight loss at a liraglutide dose of 1.2 mg/qd or 1.8 mg/qd in patients with T2DM [27, 29], we also observed that the weight loss induced by beinaglutide was due to a reduction in body fat content rather than a reduction in lean tissue mass.”
InfluentialLarsen, J. R., Vedtofte, L., Jakobsen, M. S. L., Jespersen, H. R., Jakobsen, M. I., Svensson, C. K., Koyuncu, K., Schjerning, O., Oturai, P. S., Kjaer, A., et al. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1220 · Cited by 250
Metformin: An Old Drug with New Applications
Zhou, J., Massey, S., Story, D., & Li, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102863 · Cited by 233 · cited 3×
“This observation sup - ports that reported by previous studies, in which there was no oc - currence of hypoglycaemia associated with metformin use in non-diabetic patients who are overweight/obese [17, 18].”
Warkentin, L. M., Das, D., Majumdar, S. R., Johnson, J. A., & Padwal, R. S. (2014) · Obesity Reviews · doi:10.1111/obr.12113 · Cited by 198
Feng, W., Gao, C., Bi, Y., Wu, M., Li, P., Shen, S., Chen, W., Yin, T., & Zhu, D. (2017) · Journal of Diabetes · doi:10.1111/1753-0407.12555 · Cited by 164 · cited 6×
“In the present study, the observed reduction in trunk fat content, particularly in the android region, in response to beina - glutide and metformin may help alleviate NAFLD.”
InfluentialSelf-citationLiu, X., Zhang, Y., Zheng, S., Lin, R., Xie, Y., Chen, H., Zheng, Y., Liu, E., Chen, L., Yan, J., et al. (2017) · Clinical Endocrinology · doi:10.1111/cen.13454 · Cited by 148 · cited 1×
“29 kg with 47 % of patients achieving a weight loss ≥ 5 % [23, 24].”
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 148
Feng, W., Bi, Y., Li, P., Yin, T., Gao, C., Shen, S., Gao, L., Yang, D., & Zhu, D. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12888 · Cited by 139
Self-citationRole of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111 · cited 2×
“As previ - ously observed for metformin [17], the main side effect in this study was diarrhoea.”
Jensterle, M., Kravos, N. A., Goričar, K., & Janez, A. (2017) · BMC Endocrine Disorders · doi:10.1186/s12902-017-0155-9 · Cited by 93
Lower Energy Expenditure Predicts Long-Term Increases in Weight and Fat Mass
Piaggi, P., Thearle, M. S., Bogardus, C., & Krakoff, J. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3529 · Cited by 92 · cited 2×
“A low basal metabolic rate is a risk factor for increased body weight and fat mass [35].”
Hui, F., Zhang, Y., Ren, T., Li, X., Zhao, M., & Zhao, Q. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2593-3 · Cited by 59 · cited 11×
“Similar to a previous study examining weight loss at a liraglutide dose of 1.2 mg/qd or 1.8 mg/qd in patients with T2DM [27, 29], we also observed that the weight loss induced by beinaglutide was due to a reduction in body fat content rather than a reduction in lean tissue mass.”
InfluentialZhang, Y. L., Zhou, C., Li, X. F., Yang, M. N., Tao, L., Zheng, X. Y., & Jia, Y. S. (2019) · Obesity Science & Practice · doi:10.1002/osp4.342 · Cited by 49 · cited 13×
“Similar to a previous study examining weight loss at a liraglutide dose of 1.2 mg/qd or 1.8 mg/qd in patients with T2DM [27, 29], we also observed that the weight loss induced by beinaglutide was due to a reduction in body fat content rather than a reduction in lean tissue mass.”
InfluentialStrategies to Counter Weight Loss-Induced Reductions in Metabolic Rate
Palmer, B. F., & Clegg, D. J. (2019) · Current Sports Medicine Reports · doi:10.1249/jsr.0000000000000610 · Cited by 6 · cited 1×
“Although all participants were advised to maintain a limited-energy balanced diet and engage in physical activity, more targeted muscle-building exercises and dietary adjustments may help prevent loss of muscle mass [35, 36].”
Research works printed but not linked: 2
- C D Society, 2021, Chinese guideline for the prevention and treatment of type 2 diabetes mellitus (2020 edition), Chin J Endo Metab, 37, 311
- 2019, Guideline for primary care of obesity:practice version, Chin J Gen Pract, 2020, 102
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 248
“However, when compared with other drugs used in diabetes, molecules like GLP-1 analogues have superior efficacy in reducing weight as compared to metformin.(196,199)”
BackgroundGLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
“A clinical study involving 78 non-diabetic overweight/obese patients found that BN may be a more effective treatment option for overweight/obese Chinese than metformin (43).”
BackgroundChen, K., Chen, L., Shan, Z., Wang, G., Qu, S., Qin, G., Yu, X., Xin, W., Hsieh, T., & Mu, Y. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15360 · Cited by 35
“12 These findings, which are consistent with those from previous studies on beinaglutide, 16,17 combined with lifestyle intervention in non-diabetic patients with overweight or obesity.”
BackgroundResultInfluentialUnlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
“In a clinical trial of 78 non-diabetic adults, Beinaglutide may be better than metformin for treating obesity [219].”
Metadata
- Authors
- Gao, L., Huang, H., Zhang, L., Zhang, N., Fu, Y., Zhu, D., Bi, Y., & Feng, W.
- Affiliations
- Nanjing Drum Tower Hospital (CN)
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2021-12-02
- Volume
- 130
- Issue
- 06
- Pages
- 358-367
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- PMC
- PMC9286864
- OpenAlex
- W3216965998
- Cited by
- 24
- References
- 34
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 5 · 2023: 6
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Experimental and Clinical Endocrinology & Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81970704, 81970689, 81900787, 81800752, 81800719)
- National Key Research and Development Program of China (2016YFC1304804, 2017YFC1309605)
- Jiangsu Provincial Key Medical Discipline (ZDXKB2016012)
- Key Project of Nanjing Clinical Medical Science, Key Research and Development Program of Jiangsu Province of China (BE2015604, BE2016606)
- Medical and Health Research Projects of Nanjing in Jiangsu Province of China (YKK18067)
- Project of Standardised Diagnosis and Treatment of Key Diseases in Jiangsu Province of China (2015604)
- Natural Science Foundation of Jiangsu Province of China (BK20201115)
- Drum Tower Hospital
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- metformin, weight loss, obesity, overweight, non-diabetic patients, GLP-1 receptor agonists, insulin resistance, insulin levels, fat mass, body composition, body mass index
- MeSH terms
- Body Weight, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Obesity, Peptide Fragments, Weight Loss, Overweight, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.